SCHILKE TOBIN (CFO) received a stock award from REVANCE THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 2/6/2025ACC: 0000950170-25-015362
Officer· CFO
Since Nov 2018
-201.55K
Net shares
Net seller
$357.7K
Total sold
0
Open market trades
0B · 0S
4
Total transactions
20.88K acquired · 222.44K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
−98K
Price / share
$3.65
Trade value
$357.70K
% of position
48.6%
2/4/2025
201.55K→103.56K
Common Stock
Direct
Shares
−103.56K
Price / share
—
Trade value
—
% of position
New position
2/6/2025
103.56K→0.00
Common Stock
Direct
Shares
+20.88K
Price / share
—
Trade value
—
% of position
New position
2/6/2025
0.00→20.88K
Common Stock
Direct
Shares
−20.88K
Price / share
—
Trade value
—
% of position
New position
2/6/2025
20.88K→0.00
Total
Net shares
−201.55K
Net value
-$357.70K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/4/2025 | U · U | −98K | $3.65 | $357.70K | 48.6% | 201.55K | 103.56K |
| Common Stock Direct | 2/6/2025 | D · Disposition | −103.56K | — | — | New position | 103.56K | 0.00 |
| Common Stock Direct | 2/6/2025 | A · Award | +20.88K | — | — | New position | 0.00 | 20.88K |
| Common Stock Direct | 2/6/2025 | D · Disposition | −20.88K | — | — | New position | 20.88K | 0.00 |
| Total | −201.55K | -$357.70K | ||||||
Derivative Transactions0
No derivative transactions reported